| Robert Alan Braunstein, MD | |
|
95 Madison Ave, Morristown, NJ 07960-6092 | |
| (973) 540-1223 | |
| Not Available |
| Full Name | Robert Alan Braunstein |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 52 Years |
| Location | 95 Madison Ave, Morristown, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891716262 | NPI | - | NPPES |
| 01768309 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 124588-1 (New York) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Corey M. Notis, M.d., P.a. | 1456365154 | 14 |
News Archive
Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing products to treat life-threatening infectious diseases, today announced that it amended an existing agreement with the National Institutes of Health (NIH) to significantly broaden the licensed therapeutic indications, or "field of use," for Sequella's lead drug candidate, SQ109.
It is understood that euthanasia is extremely rare in the UK and few doctors want it legalised, but campaigners for euthanasia have long argued terminally-ill patients are helped to die in secret.
The latest research adds to the long list of reasons why smokers should quit and is particularly bad news for middle-age smokers.
PIKAMAB, a biopharmaceutical company specializing in stratified medicine, announced today that it has secured exclusive rights to an issued U.S. patent (US 6,986,987) from the UAB Research Foundation. This patent pertains to the discovery that the functional polymorphism (Ser/Gly248) in the cytoplasmic domain of Fc alpha receptor determines the proinflammatory potential of serum IgA autoantibodies through cell signaling and production of cytokines such as TNF-alpha, IL-6, and IL-1β in an allele-dependent manner.
› Verified 4 days ago
| Entity Name | Corey M. Notis, M.d., P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568505881 PECOS PAC ID: 1456365154 Enrollment ID: O20060202000138 |
News Archive
Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing products to treat life-threatening infectious diseases, today announced that it amended an existing agreement with the National Institutes of Health (NIH) to significantly broaden the licensed therapeutic indications, or "field of use," for Sequella's lead drug candidate, SQ109.
It is understood that euthanasia is extremely rare in the UK and few doctors want it legalised, but campaigners for euthanasia have long argued terminally-ill patients are helped to die in secret.
The latest research adds to the long list of reasons why smokers should quit and is particularly bad news for middle-age smokers.
PIKAMAB, a biopharmaceutical company specializing in stratified medicine, announced today that it has secured exclusive rights to an issued U.S. patent (US 6,986,987) from the UAB Research Foundation. This patent pertains to the discovery that the functional polymorphism (Ser/Gly248) in the cytoplasmic domain of Fc alpha receptor determines the proinflammatory potential of serum IgA autoantibodies through cell signaling and production of cytokines such as TNF-alpha, IL-6, and IL-1β in an allele-dependent manner.
› Verified 4 days ago
| Entity Name | Livingston Vitreo Retinal Associates, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154485464 PECOS PAC ID: 5890839385 Enrollment ID: O20100222000705 |
News Archive
Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing products to treat life-threatening infectious diseases, today announced that it amended an existing agreement with the National Institutes of Health (NIH) to significantly broaden the licensed therapeutic indications, or "field of use," for Sequella's lead drug candidate, SQ109.
It is understood that euthanasia is extremely rare in the UK and few doctors want it legalised, but campaigners for euthanasia have long argued terminally-ill patients are helped to die in secret.
The latest research adds to the long list of reasons why smokers should quit and is particularly bad news for middle-age smokers.
PIKAMAB, a biopharmaceutical company specializing in stratified medicine, announced today that it has secured exclusive rights to an issued U.S. patent (US 6,986,987) from the UAB Research Foundation. This patent pertains to the discovery that the functional polymorphism (Ser/Gly248) in the cytoplasmic domain of Fc alpha receptor determines the proinflammatory potential of serum IgA autoantibodies through cell signaling and production of cytokines such as TNF-alpha, IL-6, and IL-1β in an allele-dependent manner.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Robert Alan Braunstein, MD 95 Madison Ave, Morristown, NJ 07960-6092 Ph: (973) 540-1223 | Robert Alan Braunstein, MD 95 Madison Ave, Morristown, NJ 07960-6092 Ph: (973) 540-1223 |
News Archive
Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing products to treat life-threatening infectious diseases, today announced that it amended an existing agreement with the National Institutes of Health (NIH) to significantly broaden the licensed therapeutic indications, or "field of use," for Sequella's lead drug candidate, SQ109.
It is understood that euthanasia is extremely rare in the UK and few doctors want it legalised, but campaigners for euthanasia have long argued terminally-ill patients are helped to die in secret.
The latest research adds to the long list of reasons why smokers should quit and is particularly bad news for middle-age smokers.
PIKAMAB, a biopharmaceutical company specializing in stratified medicine, announced today that it has secured exclusive rights to an issued U.S. patent (US 6,986,987) from the UAB Research Foundation. This patent pertains to the discovery that the functional polymorphism (Ser/Gly248) in the cytoplasmic domain of Fc alpha receptor determines the proinflammatory potential of serum IgA autoantibodies through cell signaling and production of cytokines such as TNF-alpha, IL-6, and IL-1β in an allele-dependent manner.
› Verified 4 days ago
Dr. Jeffrey Mark Reisman, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 131 Madison Ave, Suite 130, Morristown, NJ 07960 Phone: 973-267-1113 Fax: 973-267-0719 | |
Dr. David Joel Medford, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 95 Madison Ave, Suite 400, Morristown, NJ 07960 Phone: 973-984-5005 Fax: 973-984-5554 | |
Dr. Charles F Morgan, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 95 Madison Ave Ste 301, Morristown, NJ 07960 Phone: 973-540-8814 | |
Giselle Lynch, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 100 Madison Ave, Morristown, NJ 07960 Phone: 973-971-5000 | |
Dr. Sean C Lalin, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 330 South St, Suite 1, Morristown, NJ 07960 Phone: 973-871-2020 Fax: 973-871-2000 | |
Dr. Jayati Saha Sarkar, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 261 James St Ste 2d, Morristown, NJ 07960 Phone: 973-984-3937 Fax: 973-984-0059 | |
Dr. Lucy L Chen, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 95 Madison Ave Ste 301, Morristown, NJ 07960 Phone: 973-540-8814 |